Journal article · 2026 · Open access
Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery
International Journal of Pharmacy and Pharmaceutical Science, 8(8), 111–114 · Published 1 August 2026 · DOI 10.33545/26647222.2026.v8.i8a.497
In brief
“Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery” is a 2026 journal article by Sushrith Srinath Puttur and 2 co-authors, published in International Journal of Pharmacy and Pharmaceutical Science. OpenAlex counts 0 citations as of 19 November 2026. It is open access: the full text is free to read at International Journal of Pharmacy and Pharmaceutical Science.
- Citations
- 0
- References
- 11
- Authors
- 3
Abstract
Cardiovascular diseases (CVDs) are the most significant cause of death globally, accounting for about 17.9 million deaths annually and inflicting a huge health system burden. Despite the great progress in pharmacologic and interventional therapy, traditional drug delivery systems have issues like limited bioavailability, off-target cytotoxicity, swift systemic clearance, and patient non-compliance. Nanomedicine addresses the issue by allowing targeted and controlled drug delivery to pathologic tissues. There are varied Nanoparticle-based drug carriers such as liposomes, polymeric nanoparticles, dendrimers, and metallic nanoparticles, which have been developed to deliver cardiovascular drugs to pathologic tissues with accuracy that enhances the effectiveness of disease treatment of conditions such as atherosclerosis, myocardial infarction, and in-stent restenosis after percutaneous coronary intervention (PCI). Theranostic nanoparticles with a special ability to treat and diagnose disease simultaneously have been under research by scientists which can enable real-time imaging along with delivery of drug to pathologic tissues which can facilitate personalized treatment options for cardiovascular patients. This study describes how nanomedicine bypasses the limitations of traditional treatment, recapitulates its safety and efficacy in preclinical and clinical environments, and describes the challenges of translating these advances to the clinic. Systematic review of the literature was performed with articles from databases like PubMed, Scopus, and Web of Science. Results highlight the considerable advantages of nanomedicine in the treatment of diseases such as atherosclerosis and coronary artery disease. Anti-thrombotic drugs carried through polymeric nanoparticles have exhibited potential for prevention of clotting without excess risk of bleeding. Liposomal statins alleviate the plaque, polymeric nanoparticles optimize blood clot preclusion with lower risk of bleeding, and theranostic nanoparticles further improve dual therapy and imaging assistances. Though promising, nanomedicine's widespread clinical use requires further optimization, regulatory approval and large-scale clinical trials.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Puttur, S. S., MV, P., & Shabaraya, A. (2026). Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery. International Journal of Pharmacy and Pharmaceutical Science, 8(8), 111–114. https://doi.org/10.33545/26647222.2026.v8.i8a.497
MLA 9
Puttur, Sushrith Srinath, et al. “Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery.” International Journal of Pharmacy and Pharmaceutical Science, vol. 8, no. 8, 2026, pp. 111–114. https://doi.org/10.33545/26647222.2026.v8.i8a.497.
Chicago
Puttur, Sushrith Srinath, Prathvi MV, and AR. Shabaraya. 2026. “Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery.” International Journal of Pharmacy and Pharmaceutical Science 8 (8): 111–114. https://doi.org/10.33545/26647222.2026.v8.i8a.497.
Harvard
Puttur, S. S., MV, P. and Shabaraya, A. (2026) ‘Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery’, International Journal of Pharmacy and Pharmaceutical Science, 8(8), pp. 111–114. doi:10.33545/26647222.2026.v8.i8a.497.
IEEE
S. S. Puttur, P. MV, and A. Shabaraya, “Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery,” International Journal of Pharmacy and Pharmaceutical Science, vol. 8, no. 8, pp. 111–114, 2026, doi: 10.33545/26647222.2026.v8.i8a.497.
BibTeX
@article{puttur2026nanomedicine,
title = {{Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery}},
author = {Puttur, Sushrith Srinath and MV, Prathvi and Shabaraya, AR.},
journal = {International Journal of Pharmacy and Pharmaceutical Science},
year = {2026},
volume = {8},
number = {8},
pages = {111--114},
doi = {10.33545/26647222.2026.v8.i8a.497},
url = {https://doi.org/10.33545/26647222.2026.v8.i8a.497}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- nanomedicine
- targeted drug delivery
- cardiovascular disease
- nanoparticle drug carriers
- liposomes
- polymeric nanoparticles
- dendrimers
- metal nanoparticles
Work with this paper
Most-cited papers in Materials Science
- Electric Field Effect in Atomically Thin Carbon FilmsKostya S. Novoselov, Andre K. Geim, Sergey V. Morozov and 5 more · Science · 2004 · 67,474 citations
- Revised effective ionic radii and systematic studies of interatomic distances in halides and chalcogenidesROBERT D. SHANNON · Acta Crystallographica Section A · 1976 · 66,944 citations
- Ab initio molecular dynamics for liquid metalsGeorg Kresse, J. Häfner · Physical review. B, Condensed matter · 1993 · 46,320 citations
- Helical microtubules of graphitic carbonSumio Iijima · Nature · 1991 · 43,639 citations
- The rise of grapheneAndre K. Geim, Kostya S. Novoselov · Nature Materials · 2007 · 40,328 citations
Questions about this paper
How do I cite this paper in APA style?
Puttur, S. S., MV, P., & Shabaraya, A. (2026). Nanomedicine in cardiovascular disease treatment: Advancements in targeted drug delivery. International Journal of Pharmacy and Pharmaceutical Science, 8(8), 111–114. https://doi.org/10.33545/26647222.2026.v8.i8a.497
How many times has this paper been cited?
0 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at International Journal of Pharmacy and Pharmaceutical Science: sign in and open the PDF from this page.
Who wrote this paper?
Sushrith Srinath Puttur, Prathvi MV, AR. Shabaraya.
What is the DOI of this paper?
10.33545/26647222.2026.v8.i8a.497, permanently at https://doi.org/10.33545/26647222.2026.v8.i8a.497. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.